

Author: Kim Yoon
Publisher: Springer Publishing Company
ISSN: 0913-8668
Source: Journal of Anesthesia, Vol.24, Iss.4, 2010-08, pp. : 549-552
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18-65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient's response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (P</i> < 0.001). The number of patients showing generalized movement (response 4) with the rocuronium injection was significantly lower in nafamostat group [1 (2.2%)] than the control group [15 (33.3%)], P</i> < 0.001. Five and 10 min after nafamostat administration, measured potassium and activated coagulation time were similar to baseline values.Pretreatment with 1.5 mg nafamostat mesilate decreased withdrawal response associated with rocuronium injection.
Related content


Aprotinin and Nafamostat Mesilate in Liver Surgery: Effect on Blood Loss
Digestive Surgery, Vol. 24, Iss. 4, 2007-07 ,pp. :


By Kaminishi Y. Hiramatsu Y. Watanabe Y. Yoshimura Y. Sakakibara Y.
The Annals of Thoracic Surgery, Vol. 77, Iss. 2, 2004-02 ,pp. :






Urolithiasis associated with the protease inhibitor indinavir
By Bruce R.G. Munch L.C. Hoven A.D. Jerauld R.S. Greenburg R. Porter W.H. Rutter P.W.
Urology, Vol. 50, Iss. 4, 1997-10 ,pp. :